Drugs / edivoxetine
edivoxetine
also known as
LY2216684 · Edivoxetina · EDIVOXETINE HYDROCHLORIDE · LY-2216684 HCL · LY-2216684 HYDROCHLORIDE
Small molecule targets CYP2C19, SLC6A2 via inhibition
Trials 27
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT01460407 | Oct → Dec 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01460381 | Oct 2011 → Aug 2012 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01389765 | Jul → Aug 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01389752 | Jul → Sep 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01373931 | Jun → Dec 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01380691 | Jun → Sep 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01263093 | Dec 2010 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01263106 | Dec 2010 → Jan 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01275144 | Dec 2010 → Feb 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01263223 | Dec 2010 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01266590 | Dec 2010 → Feb 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01263119 | Dec 2010 → Feb 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01263197 | Dec 2010 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01250873 | Nov 2010 → Jan 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01241435 | Oct 2010 → Apr 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01243957 | Oct 2010 → Jan 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00840034 | Feb 2009 → Jan 2010 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00420004 | Dec 2006 → Mar 2008 | major depressive disorder | Eli Lilly and Company | Completed | Missed primary |
| Phase 2/33 trials · 2 met primary | ||||||
| Phase 2/3 | NCT00965419 | Sep 2009 → Jul 2015 | attention deficit-hyperactivity disorder | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2/3 | NCT00922636 | Jun 2009 → Dec 2010 | attention deficit-hyperactivity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 2/3 | NCT00795821 | Dec 2008 → Feb 2010 | major depressive disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 36 trials · 4 missed | ||||||
| Phase 3 | NCT01370499 | Aug 2011 → Jan 2014 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01299272 | May 2011 → Nov 2013 | major depressive disorder | Eli Lilly and Company | Completed | Missed primary |
| Phase 3 | NCT01187407 | Mar 2011 → Aug 2013 | major depressive disorder | Eli Lilly and Company | Completed | Missed primary |
| Phase 3 | NCT01185340 | Mar 2011 → Apr 2013 | major depressive disorder | Eli Lilly and Company | Completed | Missed primary |
| Phase 3 | NCT01173601 | Nov 2010 → Oct 2013 | major depressive disorder | Eli Lilly and Company | Completed | Missed primary |
| Phase 3 | NCT01155661 | Oct 2010 → Dec 2012 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-12-05 | Eli Lilly and Company | Results Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder lilly.com ↗
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-12-05 | Eli Lilly and Company | Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder lilly.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | edivoxetine | “selective norepinephrine reuptake inhibitor (NRI) edivoxetine” PMID 27685842 ↗ Mar 2017 |
| Known as | Edivoxetina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103857 ↗ |
| Known as | EDIVOXETINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103857 ↗ |
| Known as | LY-2216684 HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103857 ↗ |
| Known as | LY-2216684 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103857 ↗ |
| Known as | LY2216684 | “Drug: LY2216684” NCT00840034 ↗ |
| Action | Inhibit | “selective norepinephrine reuptake inhibitor (NRI) edivoxetine” PMID 27685842 ↗ Mar 20171“Norepinephrine transporter inhibitor” CHEMBL2103857 ↗ |
| Modality | Small molecule | — CHEMBL2103857 ↗ |
| Route | Oral | “administered orally (PO)” NCT00840034 ↗ |
| Target | CYP2C19 | “LY2216684 is only known to be a moderate inhibitor of CYP2C19” NCT01250873 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL2103857 ↗ |